You Position: Home > Paper
Targeted therapy of multiple myeloma
( views:388, downloads:104 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 9
- DOI:
- 10.3760/cma.j.issn.1006-9801.2006.09.001
- Key Word:
- 多发性骨髓瘤;靶向治疗
Abstract： 阐述抑制蛋白酶体是癌症治疗的一种新方法.波替单抗(商品名:万珂)是第一个被批准临床应用的蛋白酶体抑制剂,临床前试验表明其对许多肿瘤细胞株有效;Ⅰ期临床试验确定了最佳剂量与可处理的毒性;两个Ⅱ期试验(SUMMIT与CREST)证明万珂治疗复发和(或)难治的多发性骨髓瘤(MM)安全有效;Ⅲ期APEX试验比较万珂与大剂量地塞米松治疗复发的MM证实万珂能提高有效率、缓解持续时间和总生存期.研究者探索万珂与常规化疗和其他新药的联合.继续进行中的试验用万珂作为第一线药物治疗MM结果令人鼓舞.单用万珂或与其联合治疗恶性肿瘤值得进一步研究.
- [1]Philip, Greipp.Treatment paradigms for the newly diagnosed patient with multiple myeloma.[J].2005,42(4 Suppl 4).
- [2]Aldo Maria, Roccaro,Teru, Hideshima,Noopur, Raje,etc.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.[J].2006,66(1).
- [3]Cavenagh J,Orlowski RZ,San Miguel J,etc.A practical update on the use of bortezomib in the management of multiple myeloma.[J].2006,11(1).
- [4]Kaufman, J. L.,Lonial, S..Proteasome Inhibition: Novel Therapy for Multiple Myeloma[J].2006,29(4).
- [5]Niranjan, Yanamandra,Nandita M, Colaco,Nancy A, Parquet,etc.Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.[J].2006,12(2).
- [6]Rigacci L,Bosi A,Ciolli S,etc.Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.[J].2006,47(1).
- [7]Paul, Richardson.Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.[J].2005,42(4 Suppl 4).
- [8]Schenkein D,Dalton WS,Porter JB,etc.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.[J].2005,352(24).
- [9]Shigesaburo, Miyakoshi,Masahiro, Kami,Koichiro, Yuji,etc.Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.[J].2006,107(9).
- [10]Wilson J,Swift R,Adams J,etc.Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.[J].2006,24(6).
- [11]Saunders G.Overview of drug therapy for multiple myeloma.[J].2005,11(3).
- [12]L, Terriou,X, Leleu,I, Yakoub-Agha.[Treatment of multiple myeloma].[J].2006,93(1).
- [13]van de Velde H,Viala M,Gupta S,etc.Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.[J].2006,24(6).
- [14]Spano, J.-P.,Bay, J.-O.,Blay, J.-Y.,etc.Proteasome inhibition: a new therapeutic approach in malignancies[J].2005,92(11).
- [15]Rajni, Sinha,Jonathan L, Kaufman,Sagar, Lonial.Novel treatment approaches for patients with multiple myeloma.[J].2006,6(4).